VAXNEUVANCE® Suspension for Injection

Prescription Only

Drug type: Therapeutic

ATC code: J07AL02

Dosage form: INJECTION, SUSPENSION

Route of administration: INTRAMUSCULAR

Active ingredient: (MBC) Pneumococcal Polysaccharide Serotype 9V conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 1 conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 14 conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 23F conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 5 conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 18C conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 19F conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 4 conjugated to CRM197; (MBC) Pneumococcal Polysaccharide Serotype 6B conjugated to CRM197

Registrant

MSD PHARMA (SINGAPORE) PTE. LTD.

Approval Date

2024-02-07

Approval Number

SIN16944P

Manufacturer

MSD International GmbH T/A MSD Ireland (Carlow)

Package Insert

VAxneuvance approved PI February 2024.pdf

View